215 related articles for article (PubMed ID: 23990961)
1. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
[TBL] [Abstract][Full Text] [Related]
2. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
[TBL] [Abstract][Full Text] [Related]
4. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.
Scobie L; Hector RD; Grant L; Bell M; Nielsen AA; Meikle S; Philbey A; Thrasher AJ; Cameron ER; Blyth K; Neil JC
Mol Ther; 2009 Jun; 17(6):1031-8. PubMed ID: 19337236
[TBL] [Abstract][Full Text] [Related]
5. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.
Thornhill SI; Schambach A; Howe SJ; Ulaganathan M; Grassman E; Williams D; Schiedlmeier B; Sebire NJ; Gaspar HB; Kinnon C; Baum C; Thrasher AJ
Mol Ther; 2008 Mar; 16(3):590-8. PubMed ID: 18180772
[TBL] [Abstract][Full Text] [Related]
6.
Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.
De Ravin SS; Wu X; Moir S; Anaya-O'Brien S; Kwatemaa N; Littel P; Theobald N; Choi U; Su L; Marquesen M; Hilligoss D; Lee J; Buckner CM; Zarember KA; O'Connor G; McVicar D; Kuhns D; Throm RE; Zhou S; Notarangelo LD; Hanson IC; Cowan MJ; Kang E; Hadigan C; Meagher M; Gray JT; Sorrentino BP; Malech HL; Kardava L
Sci Transl Med; 2016 Apr; 8(335):335ra57. PubMed ID: 27099176
[TBL] [Abstract][Full Text] [Related]
8. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
9. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
10. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
[TBL] [Abstract][Full Text] [Related]
11. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.
Humbert O; Chan F; Rajawat YS; Torgerson TR; Burtner CR; Hubbard NW; Humphrys D; Norgaard ZK; O'Donnell P; Adair JE; Trobridge GD; Scharenberg AM; Felsburg PJ; Rawlings DJ; Kiem HP
Blood Adv; 2018 May; 2(9):987-999. PubMed ID: 29720491
[TBL] [Abstract][Full Text] [Related]
12. Intravenous injection of a foamy virus vector to correct canine SCID-X1.
Burtner CR; Beard BC; Kennedy DR; Wohlfahrt ME; Adair JE; Trobridge GD; Scharenberg AM; Torgerson TR; Rawlings DJ; Felsburg PJ; Kiem HP
Blood; 2014 Jun; 123(23):3578-84. PubMed ID: 24642749
[TBL] [Abstract][Full Text] [Related]
13. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
[TBL] [Abstract][Full Text] [Related]
14. Correction of SCID-X1 using an enhancerless Vav promoter.
Almarza E; Zhang F; Santilli G; Blundell MP; Howe SJ; Thornhill SI; Bueren JA; Thrasher AJ
Hum Gene Ther; 2011 Mar; 22(3):263-70. PubMed ID: 20887212
[TBL] [Abstract][Full Text] [Related]
15. Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines.
Ishikawa Y; Tanaka N; Murakami K; Uchiyama T; Kumaki S; Tsuchiya S; Kugoh H; Oshimura M; Calos MP; Sugamura K
J Gene Med; 2006 May; 8(5):646-53. PubMed ID: 16508910
[TBL] [Abstract][Full Text] [Related]
16. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
[TBL] [Abstract][Full Text] [Related]
17. Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.
Blanco E; Izotova N; Booth C; Thrasher AJ
Front Immunol; 2020; 11():608653. PubMed ID: 33329605
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Adams S; Howe SJ; Al Ghonaium A; Bayford J; Brown L; Davies EG; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra79. PubMed ID: 21865537
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of gammac-dependent cytokines-mediated immunoregulation].
Asao H
Rinsho Byori; 2007 Jan; 55(1):51-8. PubMed ID: 17319491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
